New clinical trials for nonmotor manifestations of Parkinson's disease
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Nonmotor manifestations in Parkinson's disease (PD) encompass a range of clinical features, including neuropsychiatric problems, autonomic dysfunction, sleep disorders, fatigue, and pain. Despite their importance for patients' quality of life, the evidence base for their treatment is relatively sparse. Nevertheless, the last few years have seen a number of new trials starting that specifically address nonmotor features as an outcome measure in clinical trials. Large randomized, controlled trials in the last 3 years reported improvement of psychosis with the new selective serotonin 5‐HT2A inverse agonist pimavanserin and of postural hypotension with the oral norepinephrine precursor droxidopa. Smaller new randomized, controlled trials support the effectiveness of Deep Brain Stimulation and opiates for pain, of rivastigmine for apathy and piribedil for apathy post‐DBS, group cognitive behavioral therapy for depression and/or anxiety, continuous positive airway pressure for sleep apnea in PD and doxepin for insomnia, and of solifenacin succinate and transcutaneous tibial nerve stimulation for urinary symptoms. A number of new smaller or open trials as well as post‐hoc analyses of randomized, controlled trials have suggested usefulness of other treatments, and new randomized, controlled trials are currently ongoing. © 2015 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Non-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807 · cited 16×
“Gastrointestinal Symptoms Constipation is one of the earliest symptoms of PD(75) and is a key component of the range of gastrointestinal symptoms common in PD.(76) Previously, macrogol was judged by the MDS Evidence Medicine review to be likely to effective for constipation in PD.”
BackgroundInfluentialSeppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141 · cited 19×
“D BS ) Do ub le -b lin d, ra nd om iz ed , cr os so ve r st ud y 19 PD pa tie nt s Pa in th re sh ol ds (th er m al an d m ec ha ni ca l) an d m ot or sy m pt om s un de r 3 ac ut e co nd iti on s: st im ul at io n on / m ed ic at io n of f; st im ul at io n of f/m ed ic at io n on ; an d st im ul at io n of f/m ed ic…”
BackgroundMethodInfluentialPrediagnostic presentations of Parkinson’s disease in primary care: A case-control study
Schrag, A., Horsfall, L., Walters, K., Noyce, A., & Petersen, I. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70287-x · Cited by 674
Self-citationBarone, P., Poewe, W., Albrecht, S., Debieuvre, C., Massey, D., Rascol, O., Tolosa, E., & Weintraub, D. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70106-x · Cited by 562
Apathy in Parkinson's disease: A systematic review and meta‐analysis
den Brok, M. G. H. E., van Dalen, J. W., van Gool, W. A., Moll van Charante, E. P., de Bie, R. M. A., & Richard, E. (2015) · Movement Disorders · doi:10.1002/mds.26208 · Cited by 376 · cited 1×
“Apathy Apathy may affect up to 40% of PD patients independent of cognitive impairment, yet there are few rigorous controlled trials in spite of the effect of apathy on quality of life.(42) It has been reported that apathy can markedly worsen after STN DBS(43) and subsequent to withdrawal of antiparkinsonian medication…”
BackgroundCognitive-Behavioral Therapy for Depression in Parkinson's Disease: A Randomized, Controlled Trial
Dobkin, R. D., Menza, M., Allen, L. A., Gara, M. A., Mark, M. H., Tiu, J., Bienfait, K. L., & Friedman, J. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111669 · Cited by 310 · cited 16×
“D BS ) Do ub le -b lin d, ra nd om iz ed , cr os so ve r st ud y 19 PD pa tie nt s Pa in th re sh ol ds (th er m al an d m ec ha ni ca l) an d m ot or sy m pt om s un de r 3 ac ut e co nd iti on s: st im ul at io n on / m ed ic at io n of f; st im ul at io n of f/m ed ic at io n on ; an d st im ul at io n of f/m ed ic…”
ResultInfluentialThe Parkinson Anxiety Scale (PAS): Development and validation of a new anxiety scale
Leentjens, A. F. G., Dujardin, K., Pontone, G. M., Starkstein, S. E., Weintraub, D., & Martinez‐Martin, P. (2014) · Movement Disorders · doi:10.1002/mds.25919 · Cited by 270
Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting
Uc, E. Y., Doerschug, K. C., Magnotta, V., Dawson, J. D., Thomsen, T. R., Kline, J. N., Rizzo, M., Newman, S. R., Mehta, S., Grabowski, T. J., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000644 · Cited by 230 · cited 1×
“Voice Therapy for speech impairment,(39) neurocognitive intervention and supportive therapy for with mild cognitive impairment,(40) and aerobic exercise.(41) Overall, there is some support for a class effect of dopaminergic treatments in addition to the evidence for the oral dopamine agonist pramipexole for depression…”
BackgroundRios Romenets, S., Creti, L., Fichten, C., Bailes, S., Libman, E., Pelletier, A., & Postuma, R. B. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.03.003 · Cited by 166
Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease
Ondo, W. G., Kenney, C., Sullivan, K., Davidson, A., Hunter, C., Jahan, I., McCombs, A., Miller, A., & Zesiewicz, T. A. (2012) · Neurology · doi:10.1212/wnl.0b013e3182574f28 · Cited by 112 · cited 1×
“reported on a successful short-term treatment of constipation, using lubiprostone an intestinal chloride secretagogue, in a small, double-blind, randomized, controlled study.(78) Other agents that have been studied before 2013 include linaclotide, a secretagogue,(79) plecanatide, another guanylate cyclase-C enzyme act…”
Background
Cited by
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Self-citationNon-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
Calabresi, P., Mechelli, A., Natale, G., Volpicelli-Daley, L., Di Lazzaro, G., & Ghiglieri, V. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-05672-9 · Cited by 817
Magrinelli, F., Picelli, A., Tocco, P., Federico, A., Roncari, L., Smania, N., Zanette, G., & Tamburin, S. (2016) · Parkinson's Disease · doi:10.1155/2016/9832839 · Cited by 369
Cognitive-Behavioral Therapy for Anxiety in Parkinson’s Disease
Reynolds, G. O., Saint-Hilaire, M., Thomas, C. A., Barlow, D. H., & Cronin-Golomb, A. (2020) · Behavior Modification · doi:10.1177/0145445519838828 · Cited by 59
Metadata
- Authors
- Schrag, A., Sauerbier, A., & Chaudhuri, K. R.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2015-09-15
- Volume
- 30
- Issue
- 11
- Pages
- 1490-1504
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1742073023
- Cited by
- 95
- References
- 12
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New clinical trials for nonmotor manifestations of Parkinson's disease. https://app.cochat.ai/papers/10.1002/mds.26415
- The paper
- Schrag, A., Sauerbier, A., & Chaudhuri, K. R. (2015). New clinical trials for nonmotor manifestations of Parkinson's disease. Movement Disorders. https://doi.org/10.1002/mds.26415
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.